Conflicts of interest: A review of institutional policy in Australian medical schools

Medical Journal of Australia

Volumn 194, Issue 3, 2011, Pages 121-125

  Mason, Paul R ^a   Tattersall, Martin H N ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; CONFLICT; CURRICULUM; DRUG INDUSTRY; MEDICAL SCHOOL; POLICY; REVIEW;

EID: 79951925529     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb04193.x     Document Type: Review

References (16)

1. Yager J, Feinstein RE. Medical education meets pharma: moving ahead. Acad Psychiatry 2010; 34: 92-97.
2. Campbell EG, Weissman JS, Ehringhaus SE, et al. Institutional academic industry relationships. JAMA 2007; 298: 1779-1786.
3. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006; 295: 429-433. (Pubitemid 43144979)
4. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283: 373-380. (Pubitemid 30051756)
5. Sagarin BJ, Cialdini RB, Rice WE, et al. Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion. J Pers Soc Psychol 2002; 83: 526-541.
6. Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug promotion: what we know, what we have yet to learn. Geneva: World Health Organization and Health Action International, 2005.
7. Zipkin DA, Steinman MA. Interactions between pharmaceutical representatives and doctors in training. A thematic review. J Gen Intern Med 2005; 20: 777-786. (Pubitemid 41141015)
8. Sierles FS, Brodkey AC, Cleary LM, et al. Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA 2005; 294: 1034-1042. (Pubitemid 41248444)
9. Carmody DM, Mansfield PR. What do medical students think about pharmaceutical promotion? Aust Med Student J 2010; 1: 54-57.
10. McCormick B, Tomlinson G, Brill-Edwards P, Detsky A. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. JAMA 2001; 286: 1994-1999. (Pubitemid 33010218)
11. Grande D, Frosch DL, Perkins AW, Kahn BE. Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med 2009; 169: 887-893.
12. Gundermann C, Meier-Hellmann A, Bauer M, Hartmann M. [Effects of a mandatory guideline that prohibits hospital doctors from accepting any form of benefits in any form from the pharmaceutical industry] [German]. Dtsch Med Wochenschr 2010; 135: 67-70.
13. Moynihan R. Drug company sponsorship of education could be replaced at a fraction of its cost. BMJ 2003; 326: 1163.
14. Rothman DJ, McDonald WJ, Berkowitz CD, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009; 301: 1367-1372.
15. Steinbrook R. Controlling conflict of interest - proposals from the Institute of Medicine. N Engl J Med 2009; 360: 2160-2163.
16. Australian Medical Association. Position statement on doctors' relationships with industry 2010. Canberra: AMA, 2010. http://ama.com.au/node/ 5421 (accessed Dec 2010).